---
title: "OPKO Health buys 3,685,226 Entera Bio shares at $2.17 in obesity collaboration"
url: "https://aibio.space/news/opko-health-buys-3-685-226-entera-bio-shares-2-17-obesity/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-17"
section: "Financings"
tickers: "NASDAQ:ENTX, NASDAQ:OPK"
source: "https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/exhibit_99-1.htm"
summary: "The two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Pha"
---

By the aibio.space news desk.

Sources

- [Entera Bio Ltd. 8-K (2025-03-17)](https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/exhibit_99-1.htm)

[ENTX](https://aibio.space/companies/entera-bio/) [OPK](https://aibio.space/companies/opko-health/)

2025-03-17

# OPKO Health buys 3,685,226 Entera Bio shares at $2.17 in obesity collaboration

Tickers [ENTX](https://aibio.space/companies/entera-bio/)[OPK](https://aibio.space/companies/opko-health/)

The two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1.

## Key facts

- **Companies**: Entera Bio Ltd. (NASDAQ: ENTX), OPKO HEALTH, INC. (NASDAQ: OPK)

- **News type**: Financings

- **Primary source**: [Entera Bio Ltd. 8-K (2025-03-17)](https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/exhibit_99-1.htm)

*A trading board being updated by hand. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Entera Bio Ltd. (Nasdaq: [ENTX](https://aibio.space/companies/entera-bio/)) and OPKO Health, Inc. (NASDAQ: [OPK](https://aibio.space/companies/opko-health/)) entered into a collaboration and license agreement on March 17, 2025 to advance an oral GLP-1/glucagon peptide tablet for obesity and metabolic disorders into the clinic. The program combines OPKO's long-acting oxyntomodulin analog OPK-88006 with Entera's N-Tab technology. The companies expect to file an Investigational New Drug application with the FDA later in 2025.

OPKO and Entera will hold 60% and 40% ownership interests in the program and bear 60% and 40% of development costs, respectively.

When the agreement was signed, OPKO purchased 3,685,226 ordinary shares of Entera at $2.17 per share. Entera agreed to use the proceeds to fund its 40% share of costs through Phase 1. After Phase 1, Entera can keep funding its 40% share to maintain its interest. If it opts out, Entera keeps a 15% ownership interest in the Oral OXM program, and OPKO keeps 85% and takes on development and funding.

Entera's release lists its ability to continue as a going concern absent access to sources of liquidity among the factors that could cause actual results to differ from its forward-looking statements.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

ENTX

Entera Bio Ltd.

NASDAQ · Israel

Open the starter desk

OPK

OPKO HEALTH, INC.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/opko-health-buys-3-685-226-entera-bio-shares-2-17-obesity/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "OPKO Health buys 3,685,226 Entera Bio shares at $2.17 in obesity collaboration", 2025-03-17, https://aibio.space/news/opko-health-buys-3-685-226-entera-bio-shares-2-17-obesity/